Kailera’s obesity trials are full, results due 2028
All three Phase 3 trials of the weekly shot ribupatide have finished enrolling, and the head-to-head against semaglutide is the one to watch. Roughly 4,900 people have now signed up to spend about a year and a half testing a weekly obesity injection, and most of us won’t hear how it went until the m
<p>All three Phase 3 trials of the weekly shot ribupatide have finished enrolling, and the head-to-head against semaglutide is the one to watch. Roughly 4,900 people have now signed up to spend about a year and a half testing a weekly obesity injection, and most of us won’t hear how it went until the m</p>